|
By Dross at 2009-10-23 03:36
|
Patients with MDS often ask the question "What should I do?" Here is an interesting article from the Biology of Blood and Marrow Transplantation journal that asked that very question of a number of experts.
|
|
read more | 243 reads
|
|
By Dross at 2007-10-18 02:10
|
- Exjade offers new alternative to burdensome standard therapy in children and adults who require blood transfusions for chronic anemias
- Approval makes iron chelation more accessible to patients suffering from diseases such as thalassemia, sickle cell and myelodysplastic syndromes
Basel, November 2, 2005 – Novartis announced today the first approval worldwide for Exjade® (deferasirox) – the first and only once-daily oral iron chelator – by the US Food and Drug Administration. Exjade has been approved for the treatment of chronic iron overload due to blood transfusions in adults and children age two and older.
|
|
read more | 3092 reads
|
|
By Dross at 2007-03-09 03:41
|
|
Myelodysplastic syndromes are a group of diseases in which the bone marrow does not make enough healthy blood cells.
Myelodysplastic syndromes are diseases of the blood and bone marrow. Normally, the bone marrow produces stem cells (immature cells) that develop into mature blood cells. There are 3 types of mature blood cells:
|
|
read more | 2040 reads
|
|
By Dross at 2007-03-08 04:01
|
|
Myelodysplastic syndromes (MDS) are a major and very personal target of this website. Because of this, I have found that I have been delaying the creation of this page as I have so much information I would like to include, all of it specific to an individual's FISH (cytogenetic, chromosomal) picture.
It also occurs to me that many patients that may stop by this site are missing information that could save their lives. Therefore I would like to "cut to the chase" if you will and direct you to where you should go in the meantime.
MDS is characterized by an excess of blasts in the Bone Marrow 5-20%. While you may avoid the thought of leukemiaterm when reading information on the internet, the ONLY difference between MDS and leukemia is that the term "leukemia" is only used when the number of blasts reaches 20% or more.
|
|
read more | 6 comments | 4366 reads
|
|
By admin at 2006-11-18 05:26
|
|
BRANFORD, Conn., Nov. 16 /PRNewswire-FirstCall/ -- CuraGen Corporation (NASDAQ:CRGN)
and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of Myelodysplastic Syndromes (MDS). This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for PXD101.
|
|
read more | 824 reads
|
